Bundibugyo Ebola outbreak in DRC tops 4,000 cases as WHO backs Ervebo human trial
DRC’s Bundibugyo Ebola outbreak has surpassed 4,000 confirmed cases, and WHO experts have recommended a full-scale human trial of the Ervebo vaccine to test potential cross-protection against the Bundibugyo strain.
The Democratic Republic of Congo’s Ministry of Health reports that the current Bundibugyo Ebola outbreak, declared in mid-May, has produced more than 4,000 confirmed infections and nearly 1,850 deaths. Health authorities and international agencies say the wave shows no immediate sign of slowing, raising urgent questions about containment and treatment options.
Outbreak surges past 4,000 confirmed cases
The latest official situation report records 4,053 confirmed Bundibugyo cases with 1,850 fatalities since the outbreak began in mid-May. These figures make this the largest Ebola event ever recorded in DRC and — if unchecked — a candidate to rank among the biggest outbreaks globally.
Public health officials caution that the tally likely underestimates the true burden, because surveillance and case-finding have been hampered in some areas. Epidemiologists are monitoring trends closely as case numbers and deaths continue to mount.
Spread concentrated in Ituri and neighbouring zones
The epidemic has reached 53 health zones across five provinces: Ituri, North Kivu, South Kivu, Haut-Uele and Tshopo. Ituri province accounts for the vast majority of infections, with roughly 87 percent of cases originating there, while North Kivu contributes about 11 percent.
Field teams report intense transmission in and around the provincial capital and in rural communities where movement and social disruption have complicated containment. Responders are prioritizing hotspot mapping and targeted interventions to slow further spread.
WHO endorses Ervebo trials to test cross-protection
On Friday the World Health Organization’s vaccine advisers recommended moving ahead with randomized human trials of Ervebo, the only Ebola vaccine currently licensed. The proposal seeks to determine whether Ervebo, which is approved for the Zaire Ebola strain, can offer any protection against the Bundibugyo variant now circulating.
WHO experts stressed that the trial would be conducted within the context of the ongoing outbreak and would aim to generate rigorous evidence on safety and effectiveness. The recommendation follows a review of preclinical data and programmatic considerations that weigh potential benefits against logistical and scientific uncertainties.
Preclinical evidence shows mixed but promising signals
Animal studies reviewed by the expert group produced encouraging yet cautious results. In non-human primate experiments, three of four vaccinated animals survived Bundibugyo challenge compared with one of four in control groups, suggesting partial protection in that model.
A separate unpublished ferret study of a research-grade version of Ervebo reportedly showed complete protection among vaccinated animals while all unvaccinated controls succumbed within days. Specialists emphasize that animal findings do not guarantee comparable outcomes in people and that a properly designed Phase III ring vaccination trial is required to measure human vaccine performance.
Specialists urge caution and parallel vaccine development
The United Nations’ Technical Advisory Group on Candidate Vaccine Prioritization has reiterated that a Bundibugyo-specific vaccine remains the preferred long-term solution. That advisory body warned that expectations about Ervebo’s protective effect should be realistic, noting the vaccine might reduce severe outcomes even if it does not fully block transmission or symptomatic disease.
Two candidate vaccines tailored to the Bundibugyo strain are already in early human testing, and a third is progressing toward trial readiness. Public health planners say parallel tracks — testing Ervebo while accelerating Bundibugyo-specific candidates — offer the best chance of building a layered defence.
Gavi stockpile and logistical support for trials
Gavi, the global vaccine alliance, maintains a reserve of 500,000 Ervebo doses and has indicated that vials from that stockpile can be allocated for clinical studies in the DRC. Some doses have reportedly already been moved into the country to support research and potential emergency use.
Gavi’s leadership has framed the move as a response to the outbreak’s scale and its toll on communities and frontline health workers, while also acknowledging the uncertainty around cross-protection. International partners have begun mobilizing supplies and operational support to enable trial conduct in challenging field conditions.
Operational hurdles and security concerns complicate response
The humanitarian and health response faces multiple impediments, including ongoing armed conflict in parts of the affected provinces, which disrupts surveillance, vaccination and safe burial operations. Delayed detection and limited access to diagnostic and treatment resources have further slowed containment efforts.
Transmission of Ebola occurs through contact with bodily fluids, which complicates control in densely populated or conflict-affected settings where infection prevention measures are harder to sustain. Public health teams continue to expand community engagement and logistics to reach vulnerable populations.
The global public health community is now preparing to implement a tightly governed clinical trial of Ervebo while simultaneously advancing strain-specific vaccine development. Authorities say priorities include protecting health workers, accelerating case-detection, and reinforcing laboratory and treatment capacity across the most affected health zones.
International agencies stressed that rigorous monitoring and transparent reporting will be essential as trials proceed, and that findings must be rapidly shared to guide policy. With the outbreak continuing to evolve, officials emphasized the urgency of coordinated action and the need for additional resources to support both immediate response and vaccine research efforts.
